Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA, Bevacizumab and Atezolizumab in Refractory Microsatellite Stable Colorectal Cancer
NCT05999812Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tretinoin, atezolizumab, bevacizumab in colorectal cancer (CRC), sponsored by UT Southwestern Medical Center. Started Dec 2023; status: active, not recruiting.
02
Drugs
tretinoinatezolizumabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05999812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999812.